Earning Call Transcript for meeting held on April 28, 2026
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals reported Q4 FY26 with revenue of INR64 crores (10% YoY growth) and PAT of INR9 crores (31% YoY growth). For FY26, revenue grew 7% to INR287 crores while operating profit rose 19% to INR45 crores. The company outperformed IPM significantly with 14.2% Q4 growth vs industry 10.5%, and targets 1.5x IPM growth going forward (12-15% range). The board approved INR40 crores buyback at INR250/share and recommended 200% dividend (INR4/share including special dividend of 75%), returning ~INR66 crores total to shareholders. Cash position stands at over INR190 crores with working capital cycle of just 11 days. Top 10 brands contribute 58-60% of sales. No MR additions planned; growth to come from productivity improvements. Management stated ROE to improve from 16% to 18% and ROCE from 22% to 26% post-buyback.
Strong Q4 recovery with margin expansion and aggressive capital returns signal confidence in sustained outperformance. The buyback and enhanced dividends reflect board conviction in FY27+ growth acceleration while maintaining best-in-class working capital management.